XGEN.DE
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
€ 5.4 M
ASSETS UNDER MGMT
30 bp
EXPENSES
Fund Basics
| Inception date | Jul 12, 2022 |
| Regulation | UCITS |
| Fund Website | link... |
| Distributions | |
| Currency | EUR |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| NATERA INC | 5.0 % |
| ROCHE HOLDING LTD | 4.9 % |
| ROCHE HOLDING AG-GENUSSCHEIN | 4.9 % |
| DANAHER CORP | 4.7 % |
| ELI LILLY & CO | 4.4 % |
| VERTEX PHARMACEUTICALS INC | 4.4 % |
| LONZA GROUP AG-REG | 4.4 % |
| ILLUMINA INC | 4.3 % |
| ABBOTT LABORATORIES | 4.1 % |
| AGILENT TECHNOLOGIES INC | 4.1 % |
Constituent Breakdown
| Number of holdings | 100 |
| Herfindahl-Hirschman Index | 301 |
| Wgt avg mkt cap (mns) | $94,381 |
| Large cap (>$10bn) | 77.4% |
| Mid cap ($2-10bn) | 14.2% |
| Small cap (<$2bn) | 4.2% |
| Developed mkts. | 94.4% |
| Emerging mkts. | 7.7% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 72.8 % |
 |
SWITZERLAND | 16.9 % |
 |
CHINA | 7.7 % |
 |
NETHERLANDS | 3.2 % |
 |
BRITAIN | 0.6 % |
Historical Performance
Standardized Performance (as of 02/28/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -1.5% | 5.8% | 2.5% | 1.0% | -- | -- | -- | -2.2% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | -- | 0.0% |
| Total Returns | -1.5% | 5.8% | 2.5% | 1.0% | -- | -- | -- | -2.2% | Ann. Volatility | 19.7% | 21.0% | 18.6% | 17.6% | -- | -- | -- | 18.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.16 | 2% |
| MSCI EAFE | 0.13 | 1% |
| MSCI Emg Mkts | 0.19 | 3% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.5% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $29.69 |
| Relative strength (RSI) | 49 |
| MACD/Signal | -0.17/-0.22 |
| Bollinger Bands (Upper/Lower) | $30.15/$28.68 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XGEN.DE |
Expenses vs. XGEN.DE |
ALTAR Score™ vs. XGEN.DE |
|---|---|---|---|---|
| XNNV.DE | Xtrackers MSCI Innovation UCITS ETF 1C | 32.4% | 0 bp | +3.5% |
| GNOM.L | Global X Genomics & Biotechnology UCITs ETF | 31.8% | +20 bp | -3.7% |
| BTEC.L | iShares Nasdaq US Biotechnology UCITS ETF | 31.0% | +5 bp | -0.6% |
| BTEE.L | iShares Nasdaq US Biotechnology UCITS ETF | 31.0% | +5 bp | -0.6% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 28.0% | +10 bp | +2.2% |
| XDG3.DE | Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 25.0% | +5 bp | +5.8% |
| XDWH.DE | Xtrackers MSCI World Health Care UCITS ETF 1C | 21.5% | -5 bp | +6.4% |
| XUHC.DE | Xtrackers MSCI USA Health Care UCITS ETF 1D | 16.3% | -18 bp | +6.5% |
| XUHL.DE | Xtrackers MSCI USA Health Care UCITS ETF 1C | 16.3% | -18 bp | +6.1% |
| XSLI.DE | Xtrackers SLI UCITS ETF 1D | 15.5% | -5 bp | +6.0% |
Risk and Returns: XGEN.DE vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (EUR)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/5/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.3%
ALTAR SCORE™
6th
PERCENTILE
AVOID
ETFRC RATING
There are 579 funds in the Global Equity category with an average
ALTAR Score™ of 4.6% and a standard deviation
of 2.7%. XGEN.DE's ALTAR Score™ is approximately -1.6 standard
deviations above the category average. This places XGEN.DE in the 6th percentile
among funds in the category.
Sell-Side Consensus
€37.08
PRICE TARGET
+29.6%
UPSIDE